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Background: The aim of the present study was to evaluate the predictive value of a novel quantitative measure for
the spatial heterogeneity of FDG uptake, the asphericity (ASP) in patients with non-small cell lung cancer (NSCLC).
Methods: FDG-PET/CT had been performed in 60 patients (15 women, 45 men; median age, 65.5 years) with newly
diagnosed NSCLC prior to therapy. The FDG-PET image of the primary tumor was segmented using the ROVER 3D
segmentation tool based on thresholding at the volume-reproducing intensity threshold after subtraction of local
background. ASP was defined as the relative deviation of the tumor’s shape from a sphere. Univariate and
multivariate Cox regression as well as Kaplan-Meier (KM) analysis and log-rank test with respect to overall (OAS)
and progression-free survival (PFS) were performed for clinical variables, SUVmax/mean, metabolically active
tumor volume (MTV), total lesion glycolysis (TLG), ASP and “solidity”, another measure of shape irregularity.
Results: ASP, solidity and “primary surgical treatment” were significant independent predictors of PFS in multivariate
Cox regression with binarized parameters (HR, 3.66; p < 0.001, HR, 2.11; p = 0.05 and HR, 2.09; p = 0.05), ASP and
“primary surgical treatment” of OAS (HR, 3.19; p = 0.02 and HR, 3.78; p = 0.01, respectively). None of the other
semi-quantitative PET parameters showed significant predictive value with respect to OAS or PFS. Kaplan-Meier
analysis revealed a probability of 2-year PFS of 52% in patients with low ASP compared to 12% in patients with
high ASP (p < 0.001). Furthermore, it showed a higher OAS rate in the case of low versus high ASP (1-year-OAS,
91% vs. 67%: p = 0.02).
Conclusions: The novel parameter asphericity of pretherapeutic FDG uptake seems to provide better prognostic
value for PFS and OAS in NCSLC compared to SUV, metabolic tumor volume, total lesion glycolysis and solidity.
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Lung cancer is the leading cause of cancer death and the
second most frequently diagnosed cancer [1]. The TNM
classification is accepted as the standard for therapy
stratification [2]. Tumor staging based on the TNM
classification is also known to be a strong predictor of
prognosis [2]. Age, race, gender, tumor size, histology,* Correspondence: Ivayla.apostolova@med.ovgu.de
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article, unless otherwise stated.and grade have also been shown to be independent predic-
tors of survival [3]. Initial staging in patients with newly di-
agnosed NSCLC is needed to select the most appropriate
therapeutic strategy and to determine prognosis. Combined
positron emission tomography/computed tomography
(PET/CT) using the tracer F-18-fluorodeoxyglucose
(FDG) has been reported to be superior to conventional
imaging modalities including CT and MRI in cancer
staging especially for detection of nodal and metastatic site
involvement [4]. By providing metabolic tumor charac-
terization beyond clinical and structural information [5],
FDG-PET has the potential to contribute independently totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Surgery only 11 (18)
Surgery + CTx 14 (23)
Surgery + RCTx 14 (23)
Primary RCTx 21 (35)
CTx = chemotherapy; RTx = radiotherapy; RCTx = radiochemotherapy.
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specific treatment associated with in-vivo tumor biology.
Several studies suggest that high FDG uptake in the
primary tumor at initial staging, mainly characterized
by standardized uptake value (SUV), is associated with
worse outcome in patients suffering from NSCLC
[6-9]. Other studies propose the metabolic tumor
volume (MTV) as a prognostic factor of disease recur-
rence and survival [10]. However, there are also studies
in which the prognostic value of both these measures
at initial staging is found to be unsatisfactory in
NSCLC [11-14].
There is increasing recognition that the heterogeneity
of pretherapeutic FDG uptake in the primary tumor can
provide predictive information in several solid tumors
[15,16]. Quantifying the heterogeneity of FDG uptake
appears promising for the prediction of therapy outcome
as it might reflect the biological variability causing this
intratumoral heterogeneity [17].
An increasing number of different measures have been
proposed to quantify the voxel-wise or shape heterogen-
eity of tracer uptake [16,18-20]. Some previous studies
show encouraging results in prediction of treatment out-
come from pretherapeutic FDG-PET, based on hetero-
geneity of uptake characterized by textural features in
different carcinomas [16,20]. Heterogeneity of FDG uptake,
as measured by textural features, was shown to be a
predictive factor also in patients with NSCLC [21,22]. A
measure of shape irregularity of the tumor’s FDG uptake
was proposed by Eary et al. and has been shown to be asso-
ciated with overall survival in certain types of sarcoma [18].
We were able to show that ‘asphericity’ (ASP), as a
parameter for quantification of the spatial irregularity
of FDG uptake, is a promising prognostic factor for
tumor progression and outcome in patients with pri-
mary head and neck cancer [15]. The aim of this study
was to evaluate the independent prognostic value of
ASP in patients with NSCLC prior to therapy with
respect to progression-free (PFS) and overall survival
(OAS) in addition to conventional quantitative PET
parameters such as SUVmax, SUVmean, metabolic
tumor volume (MTV) and total lesion glycolysis (TLG)
as well as relevant clinical parameters. Additionally, we
compared ASP in terms of prognostic significance to
another, previously described measure for quantitative
characterization of shape irregularity of FDG uptake,
the so-called “solidity” [19].
Methods
Patients
Patients were included retrospectively from our PET/CT
database from February 2011 to July 2013 according to
the following inclusion criteria: (i) patients had been
referred for whole-body FDG-PET for staging of NSCLCprior to treatment, (ii) NSCLC was proven histologically,
(iii) the primary tumor was clearly visible in the FDG-
PET, (iv) histopathology and/or clinical/radiological
follow-up of at least 12 months was available, (v) patients
were treated with curative intent, (vi) the primary tumor
measured at least 3 ml (the approximate lesion size that
can be reliably delineated with the used delineation
algorithm [23]). Patients in advanced stages with distant
metastases (UICC stage IV) and patients treated with
palliative intent were excluded from the analysis. This
resulted in the inclusion of 60 patients (15 women, 45
men; mean age, 65.1 ± 9.5 years; median, 65.5 years;
range, 45.9 - 80.6 years). Thirty-four of the tumors were
adenocarcinomas, 23 were squamous cell carcinomas,
one was a large-cell lung carcinoma and in 2 patients
no histological subclassification was possible. Patient
characteristics are summarized in Table 1. Tumor
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of local or regional recurrence, local tumor progression,
distant metastases or a combination of these.
The study protocol had been approved by the Ethics
Committee of the University Hospital Magdeburg A. ö. R.
at the Otto-von-Guericke University (reference number,
159/13; RAD233) and complied with the Declaration of
Helsinki.
PET imaging
Patients received a whole-body PET/CT examination
with 18-F-FDG (Biograph mCT 64, Siemens Medical,
Erlangen, Germany). The PET protocol included a
fasting period of at least 8 h followed by confirmation
of a blood glucose level ≤150 mg/dl prior to the
scanning procedure. PET scans were performed at a
median of 64.2 min (IQR, 62.2 - 69.9 min) after in-
travenous injection of 179 to 254 MBq (median,
235 MBq) of FDG. Whole-body imaging was per-
formed from base of the skull to the proximal femora
(5–7 bed positions; emission (each), 3 minutes). PET
images were derived from a 200 × 200 acquisition
matrix and were iteratively reconstructed with scatter
correction using Siemens ultraHD-PET algorithm
(2 iterations, 21 subsets). The algorithm uses time-of-
flight (TOF) analysis and accounts for the point spread
function (PSF) of the specific scanner (Siemens® Health-
care, Erlangen, Germany). An attenuation map was gen-
erated from the whole-body low-dose CT (50 mAs/
120 kV; detector collimation, 16 × 1.2 mm; exposure
time, 0.5 s; spiral pitch factor, 0.8) reconstructed with a
slice thickness of 5 mm (matrix size, 512 × 512; voxel
size, 1.5 × 1.5 × 5.0 mm).
Image analysis
The metabolically active part of the tumor was delin-
eated by an automatic algorithm based on adaptive
thresholding, taking the local background into account
[23]. VOI definition and VOI analysis were performed
by two observers in consensus to fully include the pri-
mary tumor and exclude neighboring tissues using the
software ROVER (ABX, advanced biochemical com-
pounds GmbH, Radeberg, Germany). Detailed descrip-
tion of the algorithm was published elsewhere [23,24].
The result of the automatic delineation was inspected
visually and corrected manually if non-tumor parts were
included in the segmentation volume. The ASP of the
resulting volume of interest (VOI) was computed to-
gether with SUVmax, SUVmean, the metabolic tumor
volume (MTV = VOI volume) and the total lesion gly-
colysis (TLG =MTV * SUVmean) [15] The SUV was
calculated with respect to total body weight according to
the formula: SUV = tracer concentration in tissue (MBq/
ml)/injected dose (MBq) × total body weight (kg). Both,tracer concentration in tissue and injected dose were
decay corrected to the start time of the PET emission
scan.
Asphericity (ASP)









where S and V are the surface and volume of the MTV,
respectively.
The rationale for this definition is described in detail
in a recent publication of our group [15]. ASP is inde-
pendent of the lesion size. It is zero for spherical lesions
and is larger than zero for all other lesion types. ASP =
0.5 = 50%, for example, means that the surface of the
lesion is 50% larger than the surface of a sphere with the
same volume. Thus, ASP is a quantitative measure of
shape irregularity caused by necrotic tumor parts or
invasive growth. Figure 1 shows orthogonal slices of
three examples.
Solidity
For comparison of ASP with another published measure
of spatial irregularity, we included the solidity in our
analysis. For computation of solidity, we followed the de-
scription of el Naqa et al. [19], where solidity is defined
as the proportion of voxels inside the convex hull of the
ROI which are also inside the ROI itself. The convex
hull was computed with the geometry package of R
language and environment for statistical computing
version 3.0.2, which uses the QHull algorithm [24]. The
remaining ROI analyses were performed with ROVER
version 2.1.20 (ABX, Radeberg, Germany).
Statistical analysis
Data were analyzed using the R software (Version 2.15.3,
The R Foundation for Statistical Computing, Vienna,
Austria, http://www.R-project.org). Non-parametric dis-
tribution of parameters was assumed for histograms and
Q-Q plots. Median and interquartile ranges (IQR) were
therefore used as descriptives. The correlation of metric
variables was tested by the Spearman’s rank correlation
method and illustrated by scatter plots.
The association of PFS and OAS with all clinically
relevant parameters (gender, histology, tumor stage (T3/
T4 vs. T1/T2), UICC stage (III vs. I/II), primary tumor
localization (central vs. peripheral), different treatment
strategies), as well as all quantitative PET parameters
were analyzed using univariate Cox proportional-hazards
regression, in which the PET parameters were included as
metric values. Additionally, metric parameters were binar-
ized using cut-offs. The thresholds for survival analysis
Figure 1 Orthogonal images of three representative examples of tumors with comparable MTV (range, 115–121 ml) but different ASP
values: (A) 18%, (B) 38% and (C) 156%. Segmentation volume of the metabolically active tumor indicated by red line.




IQR 15.3 - 22.7
Range 4.6 - 37.0
SUVmean
Median 8.5
IQR 6.9 - 11.8
Range 3.0 - 21.8
MTV (ml)
Median 42.7
IQR 10.0 - 76.5
Range 3.2 - 361.7
TLG (ml)
Median 355.5
IQR 81.3 - 718.6
Range 14.2 - 2980.9
ASP (%)
Median 26.3
IQR 16.5 - 50.5
Range 0.2 - 155.8
Solidity
Median 64.9
IQR 58.2 – 70.6
Range 41.9 – 78.7
Median, IQR and range of SUVmax, SUVmean, metabolic tumor volume (MTV),
total lesion glycolysis (TLG), ASP and solidity.
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does not consider survival times and censored data. Opti-
mal thresholds were therefore calculated by performing
univariate Cox regression for each measured data value
and the threshold leading to the hazard ratio with the
highest significance was taken as optimal cut-off. In order
to avoid too small group sizes only data values within the
interquartile range were considered as optimal cut-off.
The impact of the resulting binarized parameters on PFS
and OAS was analyzed using univariate Cox regression,
Kaplan-Meier curves and log-rank test. Furthermore, the
predictive value of ASP was analyzed in multivariate Cox
regression including parameters which showed a tendency
to significance (p ≤ 0.10) in the univariate analysis (MTV,
surgery and ASP). TLG was excluded from multivariate
analysis due to high collinearity with MTV. Statistical sig-
nificance was assumed at a p-value of less or equal to 0.05.
Results
Patient outcome
Patients had an overall survival rate of 73.3% with a me-
dian OAS of survivors of 20.0 months (IQR, 15.5 -
24.3 months). Sixteen patients died after a median time
of 10.2 months (IQR, 7.3 - 15.6). Recurrence or progres-
sion occurred in 29 patients after a median time period
of 8.9 months (IQR, 5.5 - 14.0 months).
Quantitative PET parameters
Descriptive values of SUVmax, SUVmean, MTV, TLG,
ASP and solidity are given in Table 2. TLG and MTV were
strongly correlated (rho = 0.96, p < 0.001). There was a
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p < 0.001) and no significant correlation between ASP and
SUVmax (Figure 2, A-B). Solidity was significantly in-
versely correlated with ASP (rho = −0.79, p < 0.001) but
not with SUVmax and MTV (Figure 2, D-F)
PFS
The results of the univariate Cox regression with respect to
PFS of the PET parameters as metric variables are shown
in Table 3. There was a significant effect for ASP (p < 0.01)
but neither for SUVmax, SUVmean, MTV, TLG or solidity,
nor for the clinical parameters. However, a tendency to
significance was observed for primary surgical treatment
(with vs. without, HR, 1.9; p = 0.09). After binarization of
metric parameters the univariate Cox regression showed a
significant effect of ASP (cut-off, 46.6%) with an HR of 3.4
(p = 0.001; Table 4) whereas no significant effect was seen
with conventional semi-quantitative PET parameters. Solid-
ity, however, showed a significant effect after binarization
(HR, 2.2; p = 0.03, cut-off 58.3). Multivariate Cox regression
including binarized ASP and “primary surgical treatment”
revealed an HR of 3.7 (p < 0.001) for high ASP, and an HR
of 2.1 (p = 0.05) for “no primary surgery”. Multivariate Cox
regression with solidity and “primary surgical treatment” as
input parameters included only solidity (HR, 2.11; p = 0.05)
in the final model. Kaplan-Meier curves for PFS in associ-
ation with binarized SUVmax, MTV, TLG, ASP and solidity
are shown in Figure 3.
OAS
The results of univariate Cox regression with respect to
OAS for the metric variables are summarized in Table 3.Figure 2 Correlations between ASP and MTV (A), ASP and SUVmax (B
SUVmax (E), solidity and ASP (F).A significant effect was observed only for ASP (p = 0.03)
and “primary surgical treatment” (p = 0.01), while a ten-
dency towards significance was seen for MTV (p = 0.07)
and the treatment combination surgery + CTx (HR, 2.8;
p = 0.07). In univariate Cox regression analysis including
binarized parameters an HR of 3.0 (p = 0.03) was observed
for ASP (cut-off, 50.2%) whereas other semi-quantitative
parameters showed no significant effect (Table 4). Multi-
variate Cox regression analysis with ASP and “primary
surgical treatment” included both parameters in the final
model for prediction of OAS (ASP: HR, 3.2; p = 0.02; “no
surgery”: HR, 3.8; p = 0.01). Multivariate Cox regression
analysis with MTV and “primary surgical treatment” as
input parameters included only surgical treatment (HR, 4.0;
p = 0.008) but not MTV (HR, 2.2; p = 0.13) in the final
model. Multivariate analysis with surgical treatment and so-
lidity as input parameters also included only surgical treat-
ment in the final model (HR, 3.7; p = 0.01). Kaplan-Meier
curves with respect to OAS for binarized SUVmax, MTV,
TLG, ASP and solidity are depicted in Figure 4.
Discussion
High heterogeneity of tumors with respect to various
biological parameters is known to be associated with
aggressive tumor behavior, response to therapy and
survival in a number of cancer types [17,25]. This is the
rationale for the quantitative evaluation of the hetero-
geneity of the FDG-PET uptake in tumor lesions, which
is assumed to capture the heterogeneity of tumor biol-
ogy to some extent, although the exact relationship has
not yet been fully elucidated. FDG-PET based hetero-
geneity measures have been found to be superior to) and TLG and MTV (C), solidity and MTV (D), solidity and
Table 3 Univariate Cox proportional-hazards regression (metric variables) with respect to PFS and OAS
Variable PFS OAS
HR 95%-CI p-value HR 95%-CI p-value
SUVmax 1.00 0.94 - 1.06 0.94 0.97 0.91 - 1.05 0.48
SUVmean 0.99 0.88 - 1.10 0.80 0.91 0.78 - 1.06 0.21
MTV 1.00 1.00 - 1.01 0.49 1.01 1.00 - 1.01 0.07
TLG 1.00 1.00 - 1.00 0.89 1.00 1.00 - 1.00 0.21
ASP 1.01 1.00 - 1.03 0.009 1.02 1.00 - 1.03 0.03
Solidity 0.97 0.93 - 1.01 0.12 0.98 0.92 – 1.03 0.39
Gender: female 1.05 0.44 - 2.46 0.92 0.44 0.10 - 1.95 0.28
Histology: adenocarcinoma 0.90 0.21 - 3.90 0.89 1.04 0.13 - 8.17 0.97
Histology: SCC 0.44 0.09 - 2.07 0.30 0.70 0.08 - 5.98 0.74
Localization: central 0.68 0.31 - 1.47 0.33 2.23 0.81 - 6.10 0.12
T stage (TNM): T3/T4 0.71 0.31 - 1.61 0.41 1.24 0.45 - 3.42 0.68
UICC stage: III A-B 0.97 0.47 - 2.01 0.93 2.10 0.73 - 6.05 0.17
Surgery: no 1.90 0.91 - 3.97 0.09 3.56 1.29 - 9.83 0.01
Radiotherapy: no 0.66 0.31 - 1.41 0.28 0.40 0.13 - 1.26 0.12
Chemotherapy: no 0.66 0.23 - 1.91 0.45 0.59 0.13 - 2.60 0.49
The respective hazard ratio (HR), 95%-confidence interval (95%-CI) and p-value are displayed. SCC = squamous cell cancer; RTx = radiotherapy;
CTx = chemotherapy; RCTx = radiochemotherapy.
Significant p-values are indicated by bold numbers.
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sures including SUVs, MTV and TLG for various indica-
tions [16,18,19].
In the present study we have demonstrated that relevant
improvement of outcome prediction in patients with
NSCLC treated with curative intent can be achieved using
ASP, a novel parameter for quantitative characterization of
the shape irregularity of the FDG uptake in the primary
tumor. In curatively treated patients, binarized ASP was
an independent significant prognostic factor for both PFS
(HR, 3.4; p = 0.001) and OAS (HR, 2.97; p = 0.03) as well
as ‘primary surgical treatment’ (PFS: HR, 2.09; p = 0.05
and OAS: HR, 3.78; p = 0.01). The probability of 2-years
PFS decreased from 52% in the patients with low ASP
(≤ 46.6%) to 12% in the patients with high ASP (> 46.6%).
A similar, significant effect was observed for OAS where
1-year OAS decreased from 91% to 67% in patients with
high ASP (> 50.2%).Table 4 Results of univariate Cox regression for binarized qua
Variable PFS
Cut-off HR 95%-CI p-va
SUVmax >15.9 0.69 0.31 - 1.53 0.36
SUVmean >8.4 0.57 0.27 - 1.20 0.14
MTV (ml) >40.7 0.58 0.27 - 1.21 0.15
TLG (ml) >332.6 0.65 0.31 - 1.36 0.25
ASP (%) >46.6 3.44 1.61 - 7.33 0.001
Solidity <58.3 2.24 1.25 - 5.58 0.03
Significant p-values are indicated by bold numbers.A pilot study of the novel parameter suggested that
ASP is a strong independent predictor of outcome in
patients with primary manifestation of head and neck
cancer. Univariate Cox regression revealed hazard ratios
of 7.8 and 7.4 for PFS and OAS, respectively [15]. The
hazard ratios associated with high ASP were somewhat
lower in the NSCLC patient group of the present study.
In head and neck cancer we found that combining
ASP with the MTV further improved the predictive
power (HR, 22.7 for PFS and 13.2 for OAS), despite a
moderate correlation between MTV and ASP similar to
the correlation between MTV and ASP in the present
study (rho = 0.54, Figure 2A). The factors that mediate a
positive correlation between ASP and MTV include
spatial resolution and necrosis. Limited spatial resolution
of PET imaging causes small lesions to appear more
spherical (lower ASP) than they actually might be.
Necrosis, which results in increased ASP by producingntitative PET parameters
OAS
lue Cut-off HR 95%-CI p-value
>17.2 0.44 0.16 - 1.19 0.11
>9.0 0.41 0.14 - 1.19 0.10
>75.5 1.78 0.64 - 4.90 0.27
>82.5 0.48 0.18 - 1.29 0.14
>50.2 2.97 1.10 - 8.00 0.03
<66.8 2.42 0.78 - 7.52 1.12
Figure 3 Kaplan-Meier curves for the quantitative PET parameters SUVmax (A), MTV (B), TLG (C), ASP (D) and solidity (E) with respect
to PFS. Cut-off values and p-values are shown on each panel.
Figure 4 Kaplan-Meier curves for the quantitative PET parameters SUVmax (A), MTV (B), TLG (C), ASP (D) and solidity (E) with respect
to OAS. Cut-off values and p-values are shown on each panel.
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http://www.biomedcentral.com/1471-2407/14/896additional internal surface area within the MTV (Figure 1),
is more likely to occur in large tumors than in small ones.
However, the fact that the correlation between ASP and
MTV was only moderate suggests that the two parameters
are not redundant. Nevertheless, in the present study
the combination of ASP and MTV did not improve the
predictive power over ASP alone (data not shown). This
accords with the fact that MTV provides weaker prog-
nostic power in NSCLC in comparison to head and
neck cancer [15].
None of the conventional PET metabolic parameters,
including SUVmax, SUVmean, MTV and TLG, showed
a significant predictive effect in the current study. Previ-
ous studies of the prognostic value of SUVs in NSCLC
reported rather variable results. A few studies reported
an association between high SUV and poor prognosis in
early stage [6-8] as well as locally advanced stage NSCLC
[9]. However, other studies did not support this finding
[11,12]. For example, a large multicenter study including
250 patients treated with primary radiochemotherapy found
no significant prognostic value of pretreatment SUVs; only
posttreatment SUVs were found to be associated with sur-
vival [12]. The level of evidence is similar for the volumetric
PET parameters MTV and TLG. Most published studies re-
port an association between survival and these volumetric
PET parameters [10,26-28], however, contradictory results
have also been published [13,14]. For example, Soussan
et al. found only the post- to pretreatment difference of
volumetric PET parameters to be predictive of outcome in
patients with stage III NSCLC; pretreatment parameters
alone were not predictive. The somewhat conflicting results
on the prognostic value of conventional pretreatment
FDG-PET measures in the literature suggest that their
prognostic value is rather limited and therefore underline
the importance of identifying novel PET parameters which
provide stronger predictive power for risk stratification
from the baseline PET prior to therapy.
Concerning clinical parameters, previous studies have
demonstrated the prognostic value of both patient charac-
teristics, e.g. age or ECOG performance status [3], and
tumor specific characteristics, e.g. tumor stage, histological
differentiation, blood vessel infiltration, lymph vessel infil-
tration and biological markers [29]. In the present study,
only one of the clinical parameters considered, primary
treatment strategy, reached the level of statistical signifi-
cance as prognostic factor. This might be due to the fact
that the sample size did not provide sufficient statistical
power to detect such effects. This suggests that the prog-
nostic value of these clinical variables is lower than the
prognostic value of the ASP in pretreatment FDG-PET.
Having undergone primary surgical treatment was a pre-
dictor of outcome in the present study, particularly with
respect to OAS. This is in accordance with the results of
large therapy trials [30].There are two recent studies on the use of textural
heterogeneity measures in NSCLC. Cook et al. demon-
strated that high heterogeneity of FDG uptake in the
primary tumor, as characterized by textural features, was
associated with non-response to chemoradiotherapy and
poor prognosis. In agreement with the present study nei-
ther SUVs nor volumetric parameters were found to be
predictive [21]. Tixier and co-workers compared a visual
score of heterogeneity with quantitative heterogeneity
measures based on textural analysis in a mixed popula-
tion of lung cancer patients (n = 102) [22]. The authors
found that the visual score correlated with the quantita-
tive heterogeneity measures, but only the quantitative
measure provided independent prognostic value. This
finding supports the use of quantitative measures, which
are determined either fully or semi-automatically and
are therefore not limited by intra- and inter-reader vari-
ability. In addition, the continuous range of values of
quantitative measures most probably allows for better
discrimination than visual scores with only a few discrete
values. Beside textural features, several other parameters
were found to be predictive for OAS (but not PFS) in
the study of Tixier et al. These were SUVmean and
MTV, as well as surgical treatment; the latter in agree-
ment with the present study.
The textural features used by Cook et al. and Tixier et al.
mainly characterize the voxel-wise heterogeneity of the
FDG uptake within the tumor. In contrast, ASP is a quanti-
tative measure of the irregularity of the 3-dimensional con-
tour of the tumor in its FDG-PET image, i.e. the ASP
depends on the shape of the surface of the metabolically
active volume, but it is not sensitive to the variability of the
FDG uptake in interior tumor voxels. The shape-based
measure ASP therefore depicts different information on
tumor heterogeneity to textural features based on voxel-by-
voxel variability of tracer uptake. An advantage of ASP
compared to other measures of heterogeneity is that it is
easily computed (just by counting voxels) from the ROI
which delineates the metabolically active part of the tumor,
since only the volume and the surface area of this ROI are
required. Thus, computation of ASP is easily integrated in
any existing software which provides a ROI tool [15]. To
the best of our knowledge, the present study is the first to
evaluate the prognostic value of the shape irregularity of
FDG uptake in NSCLC.
We compared ASP to another shape-based measure of
heterogeneity, the parameter “solidity” proposed by El
Naqa and co-workers for quantitative characterization of
the convexity of the metabolically active tumor lesion
[19]. These authors identified solidity as a promising
prognostic parameter in cervical as well as head and
neck cancer. In ROC analyses solidity provided a larger
area under the curve than SUVmax and some uptake-
based textural features [19]. In the present study, solidity
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to be expected. However, in contrast to ASP, solidity
did not provide significant prognostic information
according to univariate Cox regression, either for PFS
or for OAS. Only after binarization did solidity show a
significant association with PFS (not OAS), and this
was still considerably lower than that found for ASP
(HR 2.2 versus 3.4), although the cut-off was optimized
independently for both parameters. The higher prog-
nostic value of ASP compared to solidity was con-
firmed by Kaplan-Meier and multivariate regression
analyses.
Limitations of the present study are its retrospective
character, the inclusion of patients from a single insti-
tution only, as well as the limited sample size. Our
results must therefore still be considered as prelimin-
ary. We have initiated a prospective trial to confirm
the prognostic value of ASP in a larger cohort of cura-
tively treated patients with NSCLC and to prospect-
ively test the cut-offs proposed in the present study. If
the strong prognostic power of ASP is confirmed in
this study, the clinical value of ASP for stratification of
high risk patients to intensified primary chemoradia-
tion of locally advanced NSCLC will be evaluated in
further studies.
Conclusions
The novel parameter asphericity of pretherapeutic FDG
uptake seems to provide a better prognostic value for PFS
and OAS in NCSLC than SUV, metabolic tumor volume,
total lesion glycolysis or the previously described shape
feature, solidity.
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